Publications by authors named "Patrick Miossec"

Claim this Profile
P
Post-hoc Nonparametric Analysis of Forced Vital Capacity in the COMET Trial Demonstrates Superiority of Avalglucosidase Alfa vs Alglucosidase Alfa.
Matthias Boentert, Emmanuelle Salort Campana, Shahram Attarian, Jordi Diaz-Manera, Mazen M Dimachkie, Patrick Miossec

J Neuromuscul Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease.
Gilles Tiraboschi, David Marchionni, Gilles Tuffal, David Fabre, Jean-Marie Martinez, Patrick Miossec

J Pharmacokinet Pharmacodyn· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease.
Mazen M Dimachkie, Richard J Barohn, Barry Byrne, Ozlem Goker-Alpan, Priya S Kishnani, Patrick Miossec

Neurology· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Satish K Garg, Karin Wernicke-Panten, Marek Wardecki, Daniel Kramer, Francois Delalande, Patrick Miossec

Diabetes Technol Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
Julio Rosenstock, Markolf Hanefeld, Paramesh Shamanna, Kyung Wan Min, Gabor Boka, Patrick Miossec

J Diabetes Complications· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme.
Denis Raccah, Patrick Miossec, Virginie Esposito, Elisabeth Niemoeller, Meehyung Cho

Diabetes Metab Res Rev· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Mikkel Christensen, Patrick Miossec, Bjarne Due Larsen, Ulrich Werner, Filip K Knop

Expert Opin Drug Discov· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).
Julio Rosenstock, Denis Raccah, László Korányi, Laura Maffei, Gabor Boka, Patrick Miossec

Diabetes Care· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
Bo Ahrén, Aniceto Leguizamo Dimas, Patrick Miossec, Stéphane Saubadu, Ronnie Aronson

Diabetes Care· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
Matthew C Riddle, Ronnie Aronson, Philip Home, Michel Marre, Elisabeth Niemoeller, Patrick Miossec

Diabetes Care· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
Vivian A Fonseca, Ricardo Alvarado-Ruiz, Denis Raccah, Gabor Boka, Patrick Miossec

Diabetes Care· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis